Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity

8d ago, source: Business Insider

(RTTNews) - Lipocine Inc. (LPCN) Thursday announced positive results from the Phase 2 study of its drug candidate LPCN 2401, showing significant improvement in body composition in participants with ...

Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs

7d ago, source: GlobalData on MSN

Lipocine hopes its obesity candidate LPCN 2401 could work alongside glucagon-like peptide-1 receptor agonists (GLP1-RAs) to ...

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

8d ago, source:

NDAQ:LPCN) Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity ...

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

25d ago, source: Nasdaq

SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary ...

Lipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study

22d ago, source: Business Insider

(RTTNews) - Lipocine Inc. (LPCN) reported positive topline results from a Phase 2 clinical study of LPCN 1148 in patients with cirrhosis. The study met primary and Hepatic Encephalopathy endpoints.

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

8d ago, source: Yahoo Finance

LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1% ...

Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity

8d ago, source: Nasdaq

(RTTNews) - Lipocine Inc. (LPCN) Thursday announced positive results from the Phase 2 study of its drug candidate LPCN 2401, showing significant improvement in body composition in participants ...

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

25d ago, source: Yahoo Finance

Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a ...

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

25d ago, source: Stockhouse

Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a ...

Lipocine Inc.: Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

25d ago, source: Finanznachrichten

Lipocine Inc reports results for the quarter ended in December - Earnings Summary 07.03. Lipocine GAAP EPS of -$3.14 07.03. Lipocine Inc.: Lipocine Announces Financial Results for the Full Year ...